Feb. 19 at 3:07 AM
$SLS $ABBV its Not BAT causing Unheard of Survival in these Phase 3 Transplant INELIGIBLE, Second Remission AML Patients - Its GPS. Gps is doing what its done in ALL PREVIOUS Trials, Prevent Relapse and extend Survival.
From
$5 to
$150 $ABVX was a
$5 Stock, and Climbed to
$10 in the days leading up to its Phase 3 Trial Result Announcement - (THE CURRENT SLS STAGE - CLIMBING AS WE ANTICIPATE THE GPS Phase 3 Announcement)
ABVX was at
$10 the Day the PR HIT, the Market T1 Halted - Trading Stopped and Re Opened Gapping Up to
$60 +600% in a Blink - and it Kept Climbing to a High of
$148.
From
$5 to
$150 -- Based on Phase 3 Trial Results - Some thing Very Similar is about to Happen Here.
